F. Hoffmann-La Roche Ltd

Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/ trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial (2021) Hurvitz SA, Fresco R, Afenjar K, Stroyakovskiy D, Huang CS, Wildiers H, Jung KH, et al. Conference contribution Phase II neoadjuvant study of GDC-9545+palbociclib (palbo) vs anastrozole (A) plus palbo in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC) (2021) Hurvitz SA, Fasching P, Park YH, Quiroga V, Crnjevic TB, Fresco R, Lopez-Valverde V, et al. Conference contribution A distinct CD38+CD45RA+ population of CD4+, CD8+, and double-negative T cells is controlled by FAS (2021) Maccari ME, Fuchs S, Kury P, Andrieux G, Bengsch B, Lorenz MR, Heeg M, et al. Journal article Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) plus palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study (2021) Hurvitz SA, Park YH, Bardia A, Quiroga V, Lopez-Valverde V, Steinseifer J, Moore HM, et al. Conference contribution Influence of Inter-Annotator Variability on Automatic Mitotic Figure Assessment (2021) Wilm F, Bertram CA, Marzahl C, Bartel A, Donovan TA, Assenmacher CA, Becker K, et al. Conference contribution Dataset on Bi- and Multi-nucleated Tumor Cells in Canine Cutaneous Mast Cell Tumors (2021) Bertram CA, Donovan TA, Tecilla M, Bartenschlager F, Fragoso M, Wilm F, Marzahl C, et al. Conference contribution Obinutuzumab-induced b cell depletion reduces spinal cord pathology in a cd20 double transgenic mouse model of multiple sclerosis (2020) Breakell T, Tacke S, Schropp V, Zetterberg H, Blennow K, Urich E, Kürten S Journal article First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays (2020) Boulo S, Kuhlmann J, Andreasson U, Brix B, Venkataraman I, Herbst V, Rutz S, et al. Journal article KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer (2019) Mamounas EP, Geyer CE, Huang CS, Mano MS, Loibl S, Untch M, Wolmark N, et al. Conference contribution Residual Seal Force Testing: A Suitable Method for Seal Quality Determination of (High Potent) Parenterals (2019) Bücheler J, Luemkemann J, Gieseler H, Mohl S, Streubel A Journal article